On June 25th, Red Star Capital Bureau reported that the National Medical Products Administration recently approved the listing application of Novo Nordisk's research and production of Novo Nordisk's Novo Nordisk (Smegglutide Injection for long-term weight management) in China. Novo Nordisk states that this is the world's first and currently the only weekly preparation of glucagon like peptide-1 receptor agonist (GLP-1) used for long-term weight management.
It is reported that Novoying is suitable for long-term weight management of adult patients based on controlling diet and increasing physical activity. The initial body mass index (BMI) meets the following conditions: ≥ 30kg/m2 (obesity), or ≥ 27kg/m2 to< 30kg/m2 (overweight) with at least one weight related comorbidities, such as hyperglycemia, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease. Nuoheying can achieve an average weight loss of 17% (16.8kg) and bring multiple health benefits to patients beyond weight loss, and its safety has been widely verified.
On June 25th, the concept of weight loss pills saw a sudden increase in the afternoon, with Hanyu Pharmaceutical (300199. SZ) rising 8% during the trading session. Previously, Baihua Pharmaceutical (600721. SH) hit the limit up, while Boji Pharmaceutical (300404. SZ) and Changshan Pharmaceutical (300255. SZ) followed suit.